MULTIVALENT HETEROMULTIMER SCAFFOLD DESIGN AND CONSTRUCTS

(19)

(11)

EP 2 906 237 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	19.08.2020 Bulletin 2020/34

(45)	Mention of the grant of the patent:
	15.04.2020 Bulletin 2020/16

(21)	Application number: 13816831.5

(22)	Date of filing: 12.07.2013

(51)

International Patent Classification (IPC):

C07K 16/46^(2006.01)
A61K 39/395^(2006.01)

C07K 16/28^(2006.01)
C07K 14/76^(2006.01)

(86)	International application number:
	PCT/US2013/050408

(87)	International publication number:
	WO 2014/012082 (16.01.2014 Gazette 2014/03)

(54)	MULTIVALENT HETEROMULTIMER SCAFFOLD DESIGN AND CONSTRUCTS ENTWURF UND KONSTRUKTE FÜR EIN MULTIVALENTES HETEROMULTIMERES GERÜST CONCEPTION D'ÉCHAFAUDAGES HÉTÉROMULTIMÈRES ET PRODUITS DE RECOMBINAISON

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

13.07.2012 US 201261671640 P
05.09.2012 US 201261697245 P
30.01.2013 US 201361758701 P

(43)	Date of publication of application:
	19.08.2015 Bulletin 2015/34

(73)	Proprietor: Zymeworks Inc.
	Vancouver, British Columbia V6H 3V9 (CA)

(72)	Inventors:
	DIXIT, Surjit, Bhimarao Vancouver, Bristish Columbia V6H 3V9 (CA) D'ANGELO, Igor Edmondo, Paolo Vancouver, Bristish Columbia V6H 3V9 (CA) SANCHES, Mario Vancouver Bristish Columbia V6H 3V9 (CA) NG, Gordon Yiu Kon Vancouver Bristish Columbia V6H 3V9 (CA)

(74)	Representative: Elkington and Fife LLP
	Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR Sevenoaks, Kent TN13 1XR (GB)

(56)

References cited: :

WO-A1-2012/116453
WO-A2-2010/092135
US-A1- 2005 186 664
US-A1- 2012 244 577

WO-A2-03/060071
WO-A2-2010/118169
US-A1- 2011 287 009

TAFELMEYER P ET AL: "Transforming a (beta/alpha)8-Barrel Enzyme into a Split-Protein Sensor through Directed Evolution", CHEMISTRY AND BIOLOGY, CURRENT BIOLOGY, LONDON, GB, vol. 11, no. 5, 1 May 2004 (2004-05-01), pages 681-689, XP025916620, ISSN: 1074-5521 [retrieved on 2004-05-25]
DOCKAL ET AL.: 'Five recombinant fragments of human serum albumin-Tools for the characterization of the warfarin binding site' PROTEIN SCIENCE vol. 9, no. ISS. 8, 2000, pages 1455 - 1456, XP055186742
F F An ET AL: "Fragments of Bovine Serum Albumin Produced by Limited Proteolysis: Complementary Behavior of Two Large Fragments1", , 1 January 1976 (1976-01-01), XP55385286, Retrieved from the Internet: URL:http://pubs.acs.org/doi/pdf/10.1021/bi 00669a028 [retrieved on 2017-06-26]
KRATZ ET AL: "Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 132, no. 3, 18 December 2008 (2008-12-18), pages 171-183, XP025714816, ISSN: 0168-3659, DOI: 10.1016/J.JCONREL.2008.05.010 [retrieved on 2008-11-29]


	Remarks:
	The file contains technical information submitted after the application was filed and not included in this specification

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).